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RESEARCH NOTE
Long-term effects on the progress 
of neuropathy after diabetic Charcot foot: 
an 8.5-year prospective case–control study
Rasmus Bo Jansen1,2*, Tomas Møller Christensen2, Jens Bülow3, Lene Rørdam3, Per E. Holstein4 
and Ole Lander Svendsen1,2
Abstract 
Objective: Charcot foot is a severe complication to diabetes mellitus, associated with diabetic neuropathy. Any long-
term effects of a Charcot foot on the progress of neuropathy are still largely unexplored. The objective was to investi-
gate whether a previous Charcot foot had any long-term effects on the progress of neuropathy.
Results: An 8.5-year follow-up case–control study of 49 individuals with diabetes mellitus, 24 of whom also had 
Charcot foot at baseline visit in 2005–2007. Neuropathy was assessed with a questionnaire, biothesiometry, heart rate 
variability and venous occlusion plethysmography. Of the 49 baseline participants, 22 were able to participate in the 
follow-up. Twelve had passed away in the meantime. Heart rate variability was unchanged in both groups; from 9.7 to 
7.2 beats/min (p = 0.053) in the Charcot group, and 14.3 to 12.6 beats/min (p = 0.762) in the control group. Somato-
sensoric neuropathy showed no difference between baseline and follow-up in the Charcot group (from 39.1 to 38.5 V) 
(p = 0.946), but a significantly worsened sensitivity in the control group (from 25.1 to 38.9 V) (p = 0.002). In conclu-
sion, we found that any differences in somatic or cardial autonomic neuropathy present at baseline had disappeared 
at follow-up after 8.5 years.
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Introduction
Charcot foot (CF) is an unusual bone and joint disor-
der which causes hyperemia, inflammation and degen-
eration of the weight-bearing structures in the foot. If 
left untreated it can result in spontaneous fatigue bone 
fractures, leading to deformity and ulcerations [1, 2]. 
Although the precise pathological mechanism underly-
ing the Charcot foot is unknown, it is exclusively seen in 
individuals with established peripheral neuropathy [3–5]. 
Most cases in the Western world occur in patients with 
diabetes mellitus, with an incidence rate of about 0.3% 
per year [6, 7].
We have previously shown that local autonomic 
neuropathy in the feet, assessed through a weakened 
venoarterial sympathetic axon reflex, is not directly 
related to the development of an acute Charcot foot, 
despite the increased blood flow [8] (compared to dia-
betic controls with and without somato-sensoric neu-
ropathy). Furthermore, there seemed to be a dissociation 
between local and central autonomic neuropathy (as 
measured by heart rate variability through beat-to-beat 
analysis). This supports the theory that the inflamma-
tion is provoked by repeated local microtrauma and bone 
remodelling, as suggested by others [9–12].
It is still unknown whether the chronic deformities 
from a Charcot foot are related to lasting alterations in 
systemic or local neuropathy. If so, that could account for 
some of the recurrences of Charcot foot which are so far 
somewhat unexplained [13, 14].
To investigate this we conducted a follow-up study of a 
previously well-described group of diabetes patients with 
or without a Charcot foot [8, 15, 16]. The main goal was 
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to investigate if a former Charcot foot had any long-term 
effects on somato-sensoric or autonomic neuropathy, 
including local blood flow.
Main text
Methods
A total of 49 patients were included at the baseline visit in 
2005–2007 [8, 15]. All 49 patients were followed up using 
medical records, the “Danish Register of Cause of Death” 
and the “Danish Civil Registration System”. The included 
patients were 61.7 ± 7.2 years old and were distributed as 
40 males and 9 females. Ten patients had type 1 diabetes, 
and 39 had type 2 diabetes.
At baseline in 2005–2007 all examination were per-
formed by author TMC, and at follow-up by author RBJ. 
All examinations were performed using the same equip-
ment and the same procedures. Patients were examined 
in order of their availability over an 11  months period 
at the Endocrine Research Unit at Bispebjerg Hospital, 
Denmark.
Physical examinations focused on the lower extremi-
ties including deformities, wounds and loss-of-function. 
The degree of neuropathy was assessed by the modified 
questionnaire Neuropathy Symptom Score (NSS) (Addi-
tional file 1: Appendix S1) [17, 18]. In addition, vibration 
perception thresholds was measured by biothesiometry 
(Biothesiometer, Bio-Medical Instruments Co, Newbury, 
Ohio 44065, USA), with the probe placed on the hallux 
pulpa [19–21].
Cardial Autonomic Neuropathy (CAN) was assessed 
using the heart rate variability method by utilizing the 
autonomic cardiac regulation. Measurements were 
done using PowerLab, Chart  5 v5.5 (ADInstruments 
Pty Ltd, Castle Hill, NSW, Australia). For electrocardi-
ography measurement three electrodes were placed on 
the patient’s chest. The patient was instructed to rest 
for 10  min, after which baseline readings were taken. 
The patient was then instructed to adjust their respira-
tion rate to 6 steady breaths per minute for 1 min, each 
inspiration and expiration phase taking 5 s. This was con-
trolled with a stopwatch and under constant instruction 
and monitoring. The procedure was repeated five times 
with 5 min of rest between measurements. The measure-
ments selected as results were the ones which were eval-
uated to display the best compliance to the instructions 
(based on respiration and heart-rate pattern) [22].
Blood flow in the feet was measured using venous 
occlusion plethysmography [23, 24] with a Hokanson 
EC6 Plethysmograph with a Hokanson E20 Rapid Cuff 
Inflator (Bellevue, WA, USA). The measurements were 
done with the patient lying on his/her back after a rest 
period of 30  min. The cuff was placed around the calf, 
and a fitting strain gauge was placed around the forefoot. 
Cuff pressure was 40 mmHg for 7 s, and the inflation was 
repeated 5 times on each foot.
Data are expressed as means ±  1 Standard Deviation 
(SD) unless otherwise noted. Normal distribution was 
controlled with the Shapiro-Wilks tests. T-tests and 
Mann–Whitney rank sum tests were used for compari-
sons between two data sets (parametric and non-para-
metric respectively).
For variance analysis between multiple ranked groups 
the non-parametric Kruskal–Wallis one way analysis of 
variance was used. For matched groups (e.g. baseline ver-
sus follow-up) paired t-tests and Wilcoxon signed rank 
tests were used. For compairing categorical data (2 ×  2 
tables), Chi square test was used. Results were adjusted 
using Bonferroni correction when applicable (multiple 
comparisons).
Statistics and generel data handling was done using 
IBM SPSS Statistics v. 23 by IBM Corporation, SIG-
MAPLOT v. 11.0.0.77 by Systat Software Inc., Micro-
soft Excel 2000 v. 9.0.2812 by Microsoft Corporation 
and Apache OpenOffice 4.0.1 by The Apache Software 
Foundation.
Results
Of the 49 patients at the baseline visit, 12 had passed 
away (Table 1 and Additional file 2: Figure S1). Thus, the 
mortality rate over 8.5 years was about 25%. The causes 
of death were mainly related to late stage diabetic com-
plications, and were: nephropathy (n = 3), cancer (n = 3), 
coronary artery disease (n = 2), complicated infections/
septicaemia (n = 2), postoperative pulmonary embolism 
(n = 1) and unknown (n = 1).
We were unable to reach 4 former participants, 3 of 
whom had moved abroad. Of the remaining 33, 7 didn’t 
want to participate while 4 had had some form of lower 
extremity amputation due to diabetic foot ulcers. In total, 
22 of the original 49 patients were able to participate in 
some or all of the follow-up examinations, giving the fol-
low-up visit a participation rate of 45%.
Due to the high loss-to-follow up the participants 
were pooled into two groups: Diabetes mellitus with 
or without previous Charcot foot. This distributed the 
participants in two even groups of 11 each. The group 
with diabetes and previous Charcot foot is labeled as 
“DM + CF”, and the group with diabetes but without pre-
vious Charcot foot is labeled as “DM–CF”. Antropomor-
phic data on the participants at the follow-up visit are 
listed in Table 2.
Data was tested for any possible skewering from a sur-
vivor bias due to the high mortality. We pooled the par-
ticipants with former CF (acute and chronic), and those 
without to test them in a 2 × 2 table. There was no sig-
nificant difference in mortality between the two groups 
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(p = 0.863). We divided the baseline population into fol-
low-up (n = 22) and non follow-up participants (n = 27) 
and tested the two groups against each other for varia-
tions regarding age, diabetes age, BMI, HbA1c or bioth-
esiometry without any significant finds (Additional file 3: 
Table S1).
None of the patients had had a subsequent reactiva-
tion of their Charcot foot since the baseline visit. None 
had active foot ulcers at follow-up either, though some 
patients in both groups reported having one or more foot 
ulcers in the follow-up period (n =  6 in the DM +  CF 
group and n = 3 in the DM − CF group).
In the Charcot group, 4 patients had visual foot 
deformities (assessed without x-ray) after their Charcot 
foot. All patients with CF were originally treated with 
off-loading in a removable off-loading cast, worn for an 
average of 7.7 months (range 16.0 and median 6.0), and 
all were subsequently provided with some form of spe-
cial off-loading shoe wear.
The modified NSS at follow-up showed a mean of 
3.1 points for all 22 participants, which was not sig-
nificantly different from the 2.4 points at baseline. Nei-
ther the DM + CF nor the DM – CF groups showed a 
significant difference from baseline to follow-up either 
(Table 3).
The biothesiometry measurements at baseline showed 
a significant difference between the average sensitiv-
ity in the DM + CF and the DM − CFgroups, with the 
DM + CF group’s feet having a higher vibration thresh-
old than the DM  −  CF group’s feet (p  =  0.014). The 
change in sensitivity from baseline to follow-up was sig-
nificantly increased for the DM − CFgroup compared to 
the DM + CF group (p = 0.003), to a degree that the two 
groups had comparable vibration thresholds at follow-up.
CAN was measured in 17 of the 22 participants; 2 
wished not to participate while 3 other procedures 
were unfit for analysis due to a pacemaker (n =  1) or 
the participants’ inability to cooperate to the measure-
ments (n = 2).
There was no difference in the heart rate variability at 
baseline between the DM + CF and the DM − CF groups 
(p = 0.127). The change from baseline to follow-up was 
unchanged both within the groups and between them 
(Table  3). In the DM  +  CF group (n  =  11) it changed 
from 9.7 ± 5.9 to 7.2 ± 4.0 beats/min (p = 0.053), and in 
the DM − CF group (n = 6) it changed from 14.3 ± 7.5 to 
12.6 ± 7.7 beats/min (p = 0.762).
Table 1 Distribution of  participants (all with  diabetes) at  baseline visit in  2005–2007, and  distribution and  cause 
of not participating at follow-up visit in 2015
a Please see [11, 18] for details
Groups with diabetes and Charcot 
foot
Groups with diabetes but without Charcot foot
Distribution of participants at baseline visit 
2005–2007a
Acute CF (n = 17) Chronic CF (n = 7) 1. toe amputee (n = 5) Neuropathy (n = 9) Without 
neu-
ropathy 
(n = 11)
 Passed away before follow-up 3 (17%) 3 (43%) 3 (60%) 3 (33%) 0 (0%)
 How many were amputated before death 2 2 1 0 N/A
 Unable to reach/moved abroad 1 1 1 0 1
 Declined participation 2 0 1 2 2
 Excluded due to amputation 1 2 0 1 0
 Participants available for follow-up measure-
ments
10 1 0 3 8
Distribution of participants at follow-up visit 
2015
Previous Charcot foot (DM + CF)
n = 11
No previous Charcot foot (DM − CF)
n = 11
Table 2 Antropomorphic data of  the  participants 
at  follow-up for  both  groups of  diabetics with  (DM +  CF) 
or without (DM − CF) previous Charcot foot
Data listed as #n or mean ± 1SD. None of the parameters are significantly 
different between the groups 
a Group represents pooled data from acute and chronic Charcot foot groups 
from the first study [11, 18]
b Group represents pooled data from 1.toe amputees, neuropathy and without 
neuropathy groups from the first study [11, 18]
Group DM + CF (n = 11)a DM − CF (n = 11)b
Age (years) 67.2 ± 8.3 70.4 ± 3.8
Sex (m/f ) 8/3 10/1
Diabetes type (I/II) 5/6 2/9
Diabetes duration (years) 28.0 ± 15.4 26.7 ± 12.8
Affected foot (right/left) 6/5 N/A
BMI 27.2 ± 3.2 30.0 ± 4.8
HbA1c (mmol/mol) 59.9 ± 10.2 58.3 ± 12.8
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Of the 22 participants, 19 were able to participate to 
the plethysmography; 1 did not wish to participate while 
2 were unable to complete the procedure due to discom-
fort from the cuff (n = 1), or involuntary muscle cramps 
which invalidated the measurements (n = 1).
In the DM +  CF group (n =  10) there was a signifi-
cant decrease in blood flow in the previous Charcot foot 
between baseline and follow-up (p = 0.001), as well as a 
significant difference in the change from baseline to fol-
low-up between the healthy and affected foot (p = 0.002) 
(Additional file 4: Figure S2).
There was no difference at follow-up between the blood 
flow in the DM + CF and DM − CF groups (p = 0.280). 
However, there was a significant change in the aver-
age blood flow in the DM  +  CF feet compared to the 
DM − CF from baseline to follow-up (p = 0.009), due to 
a decrease in blood flow in the DM + CF feet.
Discussion
In this study we have described a population with diabe-
tes mellitus, half of whom had a Charcot foot 8.5  years 
ago. We have focused on the possible consequences of 
this on peripheral sensoric neuropathy, CAN and blood 
flow in the foot. To our knowledge, this is the first study 
investigating a population with Charcot foot across those 
parameters long-term.
We found no differences in somato-sensoric or cen-
tral autonomic neuropathy had developed during the 
follow-up period, and that the difference in somatic neu-
ropathy present at baseline had disappeared at follow-up. 
Baseline data showed a significant difference in both sen-
sitivity and blood flow between the groups, but this had 
also disappeared at follow-up.
The worsening in sensitivity was only seen in the 
DM − CF group. The sensitivity in the DM + CF group 
did not change during the follow-up period, and nei-
ther did it differ between the healthy and the affected 
foot. This suggests that a foot developing an acute Char-
cot condition is affected equally by neuropathy as the 
contralateral foot. Overall, there seems to be no last-
ing effects of an acute Charcot foot on the progress of 
peripheral somato-sensoric neuropathy or CAN in our 
population after 8.5 years.
In our population, we see a high mortality in several of 
the baseline groups (Table 1) which is in line with previ-
ously reported mortality rates. As shown by Sohn et  al. 
[25] people with diabetes have an increased mortality 
when affected by Charcot foot and/or foot ulcers; both 
of which are commonly related to neuropathy. Especially 
diabetic neuropathic foot ulcers are known to be a major 
cause of mortality. Moulik et al. [26] report a 5-year mor-
tality of 45%, while Morbach et  al. report a cumulative 
10-year mortality for people with diabetic foot ulcers of 
70% [27].
Our main findings are that there were no differences 
between the previous Charcot foot group and control 
group with regards to somato-sensoric or autonomic 
neuropathy at follow-up. In fact neuropathy in partici-
pants with diabetes but without Charcot foot had sig-
nificantly worsened from baseline to follow-up, to be 
Table 3 Somato-sensoric and autonomic neuropathy in the groups from baseline and follow-up
Groups consists of diabetics with (DM + CF) or without (DM − CF) acute or chronic Charcot foot at baseline
Data listed as (median; range) or (mean ± 1SD)
* Significant at set level (α-level) of 0.05
+ Average of both feet in each group (DM + CF and DM − CF) compared
DM + CF (n = 11) DM − CF (n = 11) p value
Mod.NSS, baseline 2; 8 1; 6 0.946
Mod.NSS, follow-up 4; 7 3; 9 –
p value 0.250 0.557 –
DM + CF (n = 11) DM − CF (n = 11) p  value+
Healthy foot Charcot foot Right foot Left foot
Biothesiometry, baseline (V) 38 ± 15 40 ± 15 26 ± 11 24 ± 13 0.014*
Biothesiometry, follow-up (V) 38 ± 15 39 ± 15 40 ± 10 38 ± 10 –
Δfollow-up − 1 ± 11 − 1 ± 5 14 ± 13 14 ± 16 0.003*
DM + CF (n = 11) DM − CF (n = 6) p value
Heart-rate variability, baseline (beats/min) 9.7 ± 5.9 14.3 ± 7.5 0.127
Heart-rate variability, follow-up (beats/min) 7.2 ± 4.0 12.6 ± 7.7 –
p value 0.053 0.762 –
Δfollow-up − 2.5 ± 3.7 − 0.4 ± 3.2 0.274
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comparable to that of those participants with previous 
acute Charcot foot. In addition, the increased blood flow 
seen in the acute Charcot foot had, as expected, com-
pletely disappeared at follow-up 8.5  years later. Finally, 
our study confirms the high mortality for individuals 
with diabetic neuropathy.
Limitations
The main weakness of the study was the low participation 
rate in a small population. However, significant dropout 
and loss-to-follow up is often the case when dealing with 
patients with a serious disease and its complications. Due 
to the considerable loss-to-follow up, we chose to include 
all participants in as many tests as possible, even those 
who could not participate in all the tests.
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